Abstract | OBJECTIVE: METHODS: Rats with ongoing EAMG received intraperitoneal treatment with the constructs weekly for 5 weeks beginning after the acute phase. Autoantibody concentration, subclassification, and specificity were analyzed to address the underlying therapeutic mechanism. RESULTS: EAMG was specifically suppressed by diverting autoantibody production away from pathologically relevant specificities directed at epitopes on the extracellular surface of muscle AChRs toward pathologically irrelevant epitopes on the cytoplasmic domain. A mixture of subunit cytoplasmic domains was more effective than a mixture containing both extracellular and cytoplasmic domains or than only the extracellular domain of alpha1 subunits. INTERPRETATION:
Therapy using only cytoplasmic domains, which lack pathologically relevant epitopes, avoids the potential liability of boosting the pathological response. Use of a mixture of bacterially-expressed human muscle AChR cytoplasmic domains for antigen-specific immunosuppression of myasthenia gravis has the potential to be specific, robust, and safe.
|
Authors | Jie Luo, Alexander Kuryatov, Jon M Lindstrom |
Journal | Annals of neurology
(Ann Neurol)
Vol. 67
Issue 4
Pg. 441-51
(Apr 2010)
ISSN: 1531-8249 [Electronic] United States |
PMID | 20437579
(Publication Type: Journal Article, Research Support, N.I.H., Extramural)
|
Chemical References |
- Autoantibodies
- Immunoglobulin G
- Peptide Fragments
- Protein Subunits
- Receptors, Cholinergic
- Ovalbumin
|
Topics |
- Animals
- Autoantibodies
(immunology)
- Disease Models, Animal
- Enzyme-Linked Immunosorbent Assay
(methods)
- Female
- Humans
- Immunoglobulin G
(therapeutic use)
- Immunotherapy
(methods)
- Muscle, Skeletal
(immunology)
- Myasthenia Gravis, Autoimmune, Experimental
(immunology, therapy)
- Ovalbumin
(immunology)
- Peptide Fragments
(immunology)
- Protein Subunits
(immunology)
- Rats
- Rats, Inbred Lew
- Receptors, Cholinergic
(chemistry, immunology)
- Time Factors
|